Gene · 3702
Papers2,789
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,201 to 1,220 of 2,789
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro. | Cancer Sci | 2020 | 32876369 | PubTator, text mining | PubMed |
| Natural killer/T-cell lymphoma with intracranial infiltration and Epstein-Barr virus infection: A case report. | World J Clin Cases | 2020 | 32874983 | PubTator, text mining | PubMed |
| The phenotypic changes of γδ T cells in COVID-19 patients. | J Cell Mol Med | 2020 | 32864865 | PubTator, text mining | PubMed |
| Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium. | Nephrol Dial Transplant | 2020 | 32853351 | PubTator, text mining | PubMed |
| MMP25 Regulates Immune Infiltration Level and Survival Outcome in Head and Neck Cancer Patients. | Front Oncol | 2020 | 32850314 | PubTator, text mining | PubMed |
| CD70 Deficiency Associated With Chronic Epstein-Barr Virus Infection, Recurrent Airway Infections and Severe Gingivitis in a 24-Year-Old Woman. | Front Immunol | 2020 | 32849540 | PubTator, text mining | PubMed |
| Chromosomal instability associated with adverse outcome: a case report of patient with Nijmegen breakage syndrome and rapidly developed T-NHL with complex karyotype. | Mol Cytogenet | 2020 | 32843899 | PubTator, text mining | PubMed |
| Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma. | Cancers (Basel) | 2020 | 32824422 | PubTator, text mining | PubMed |
| Structure of LRRK2 in Parkinson's disease and model for microtubule interaction. | Nature | 2020 | 32814344 | PubTator, text mining | PubMed |
| Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis. | J Mol Med (Berl) | 2020 | 32808093 | PubTator, text mining | PubMed |
| ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer. | Pharmacol Res Perspect | 2020 | 32790160 | PubTator, text mining | PubMed |
| Analysis of prognostic genes in the tumor microenvironment of lung adenocarcinoma. | PeerJ | 2020 | 32775050 | PubTator, text mining | PubMed |
| Elevated levels of adiponectin associated with major adverse cardiovascular and cerebrovascular events and mortality risk in ischemic stroke. | Cardiovasc Diabetol | 2020 | 32771014 | PubTator, text mining | PubMed |
| ABL1-dependent OTULIN phosphorylation promotes genotoxic Wnt/β-catenin activation to enhance drug resistance in breast cancers. | Nat Commun | 2020 | 32770022 | PubTator, text mining | PubMed |
| Esophageal Microenvironment: From Precursor Microenvironment to Premetastatic Niche. | Cancer Manag Res | 2020 | 32765088 | PubTator, text mining | PubMed |
| TCR Signal Strength and Antigen Affinity Regulate CD8+ Memory T Cells. | J Immunol | 2020 | 32759295 | PubTator, text mining | PubMed |
| A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. | Cancer | 2020 | 32757302 | PubTator, text mining | PubMed |
| Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date. | Onco Targets Ther | 2020 | 32753893 | PubTator, text mining | PubMed |
| Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL). | Leukemia | 2020 | 32753689 | PubTator, text mining | PubMed |
| Single-Cell Heterogeneity of Cutaneous T-Cell Lymphomas Revealed Using RNA-Seq Technologies. | Cancers (Basel) | 2020 | 32751918 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3702/papers?page=61